DOCSLIB.ORG

Supplemental Table 1: Pancreatic Lesion Multiplicity in Ela-KRASG12D Mice at 14 Months of Age Depends on Genetic Background

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Supplemental Table 1: Pancreatic Lesion Multiplicity in Ela-KRASG12D Mice at 14 Months of Age Depends on Genetic Background Supplemental Table 1: Pancreatic lesion multiplicity in Ela-KRASG12D mice at 14 months of age depends on genetic background. Mouse Strain # Mice Lesion Multiplicity ± SD FVB-Tg(Ela-KRASG12D) 18 0.3 ± 0.6 G12D SWFVB-Tg(Ela-KRAS )F1 16 0.6 ± 1 G12D a C3FVB-Tg(Ela-KRAS )F1 14 4 ± 4 G12D a BALBFVB-Tg(Ela-KRAS )F1 16 8 ± 4 G12D a D2FVB-Tg(Ela-KRAS )F1 14 8 ± 4 G12D a B6FVB-Tg(Ela-KRAS )F1 18 11 ± 5 aSignificantly different from the FVB-Tg(Ela-KRASG12D) value by Wilcoxon rank sum test (P < 10-4) Supplemental Table 2 1 Supplemental Table 2: Positions of markers analyzed in linkage studies. a b c c c Marker Chrom Pos (cM) Pos (bp) B6xFVB BALBxFVB D2xFVB D1Mit70 1 17.8 32,733,289 B D1Mit5 1 32.8 63,862,105 IB D1Mit46 1 43.1 75,569,122 IB IB D1Mit83 1 52 88,043,561 IB D1Mit80 1 52 88,274,528 IB D1Mit91 1 64 128,355,210 IB D1Mit30 1 70 135,259,675 IB D1Mit102 1 73 149,096,650 IB D1Mit110 1 88.1 169,688,648 IB D1Mit15 1 87.9 170,288,805 IB IB D1Mit115 1 99.7 179,610,205 IB IB D1Mit406 1 101.2 190,093,211 IB D1Mit292 1 107.3 193,227,344 IB D2Mit6 2 12.5 20,814,594 IB I D2Mit80 2 10 20,928,232 B IB D2Mit7 2 28 38,095,233 IB IB D2Mit9 2 37 65,277,459 IB D2Mit37 2 45 74,531,830 IB D2Mit66 2 47.8 84,657,700 IB D2Mit62 2 65 117,938,185 IB D2Mit17 2 69 122,639,898 IB D2Mit30 2 69 123,526,660 IB D2Mit57 2 82 148,128,121 IB IB D2Mit285 2 86 152,683,037 IB D2Mit51 2 95.5 162,976,178 IB D2Mit148 2 105 178,535,250 IB IB D3Mit62 3 4.6 17,467,423 IB D3Mit55 3 13.8 28,475,226 IB IB D3Mit22 3 33.7 69,522,098 B D3Mit51 3 35.2 73,304,714 IB D3Mit49 3 41 89,036,582 I IB D3Mit39 3 52.5 108,572,112 IB D3Mit256 3 66.2 136,014,535 IB D3Mit17 3 71.8 143,310,189 IB IB D3Mit32 3 80.2 149,411,386 IB IB D3Mit19 3 87.6 157,646,003 IB D4Mit18 4 5.2 13,937,604 IB D4Mit1 4 6.3 17,819,763 IB D4Mit2 4 6.5 25,610,387 IB I D4Mit6 4 20.8 49,991,211 I D4Mit17 4 31.4 63,026,328 IB IB IB D4Mit348 4 40 82,826,651 IB D4Mit133 4 42.5 89,188,138 I D4Mit31 4 51.3 106,785,035 IB D4Mit52 4 54.9 114,473,276 IB D4Mit57 4 56 117,791,835 IB D4Mit54 4 66 137,446,452 IB IB D4Mit33 4 79 149,966,385 IB D4Mit356 4 81 151,804,078 IB Supplemental Table 2 2 a b c c c Marker Chrom Pos (cM) Pos (bp) B6xFVB BALBxFVB D2xFVB D4Mit256 4 82.7 154,364,548 IB IB D5Mit61 5 8 21,368,263 B D5Mit11 5 26 48,258,171 IB IB D5Mit54 5 28 50,817,671 I IB D5Mit7 5 45 93,726,231 IB D5Mit10 5 54 104,668,024 IB IB D5Mit158 5 62 115,413,178 IB D5Mit95 5 68 125,309,605 IB D5Mit30 5 72 130,061,274 IB D5Mit99 5 80 141,433,366 IB D5Mit43 5 83 145,401,297 IB IB D5Mit143 5 86 151,804,668 IB D6Mit116 6 5.5 25,100,229 IB D6Mit274 6 20.5 48,676,564 IB D6Mit17 6 30.3 71,069,212 IB D6Mit3 6 33.5 78,579,497 IB D6Mit29 6 36.5 86,756,799 IB D6Mit36 6 46 104,453,354 IB D6Mit10 6 48.7 113,297,319 IB I D6Mit44 6 51.5 115,883,287 I B D6Mit14 6 71.2 145,604,376 IB D6Mit15 6 74 146,377,508 IB IB D7Mit57 7 4 20,283,120 IB D7Mit224 7 15 33,329,325 IB D7Mit25 7 16 37,653,504 IB D7Mit31 7 44 94,642,439 I IB IB D7Mit32 7 46.4 97,308,622 IB IB D7Mit101 7 60 132,776,553 IB IB IB D7Mit223 7 72.4 151,795,777 IB IB IB D8Mit16 8 8 23,762,706 I IB D8Mit3 8 10 25,723,657 IB D8Mit24 8 18 35,705,830 B D8Mit45 8 40 89,829,274 IB IB D8Mit88 8 58 117,360,795 IB D8Mit35 8 59 118,625,692 IB D8Mit14 8 67 127,170,502 IB D8Mit42 8 71 129,076,217 IB D8Mit56 8 73 131,542,319 B D9Mit42 9 8 29,128,608 IB IB IB D9Mit4 9 29 51,931,283 IB IB D9Mit21 9 31 57,532,016 IB D9Mit11 9 48 86,133,452 B D9Mit10 9 49 89,871,843 I IB D9Mit51 9 61 106,314,608 IB D9Mit15 9 61 109,670,306 IB D8Mit46 9 61 114,588,014 IB IB D9Mit201 9 65 117,345,284 IB D9Mit19 9 71 120,271,887 IB D10Mit28 10 4 9,133,173 IB D10Mit51 10 9 18,388,995 IB Supplemental Table 2 3 a b c c c Marker Chrom Pos (cM) Pos (bp) B6xFVB BALBxFVB D2xFVB D10Mit16 10 16 21,435,099 IB D10Mit3 10 21 28,871,992 IB D10Mit40 10 29 48,420,845 IB D10Mit15 10 35 66,475,191 IB D10Mit42 10 44 82,117,849 IB D10Mit230 10 49 89,654,985 IB D10Mit10 10 51 91,754,266 IB D10Mit70 10 59 103,535,851 IB D10Mit233 10 62 113,818,252 IB D10Mit74 10 65 117,990,821 IB D10Mit35 10 69 121,642,455 IB D11Mit19 11 13 25,322,121 IB IB IB D11Mit23 11 28.1 54,049,428 IB I D11Mit4 11 37 68,422,759 B IB D11Mit38 11 49 87,614,342 IB D11Mit289 11 55 94,741,466 IB D11Mit98 11 58 96,724,981 IB D11Mit99 11 59.5 99,510,152 IB D11Mit103 11 76 117,028,633 IB D11Mit48 11 77 117,993,078 IB IB D12Mit12 12 6 25,358,023 IB IB D12Mit2 12 19 42,747,379 IB D12Mit54 12 24 54,960,589 IB D12Mit3 12 32 77,081,506 IB D12Mit5 12 37 82,010,921 IB IB D12Mit28 12 52 106,580,305 IB D12Mit133 12 56 111,536,237 IB D12Mit8 12 58 114,657,953 IB D12Nds2 12 59 115,134,928 IB D13Mit18 13 18 36,258,023 IB IB D13Mit10 13 31 49,821,373 IB D13Mit13 13 35 56,582,797 IB D13Mit9 13 45 81,241,701 IB D13Mit69 13 44 83,982,180 IB D13Mit75 13 59 107,259,982 IB D13Mit78 13 75 119,618,032 IB IB D14Mit1 14 3 12,201,958 IB D14Mit50 14 4 21,831,604 IB D14Mit2 14 5 22,716,706 IB D14Mit54 14 12.5 36,137,026 IB D14Mit18 14 16.5 48,436,964 IB D14Mit39 14 30 69,166,099 IB D14Mit68 14 39 72,914,117 IB D14Mit69 14 43 77,023,931 IB D14Mit42 14 52 108,073,441 I IB D14Mit36 14 63 124,975,953 IB B D15Mit13 15 6.7 3,410,212 IB D15Mit8 15 19.7 33,392,975 IB D15Mit5 15 22.2 43,279,930 IB IB D15Mit31 15 48.5 80,644,949 IB Supplemental Table 2 4 a b c c c Marker Chrom Pos (cM) Pos (bp) B6xFVB BALBxFVB D2xFVB D15Mit70 15 47.7 81,032,515 IB IB D15Mit262 15 51.1 87,111,041 IB D15Mit39 15 56.6 96,095,961 IB D15Mit16 15 61.7 102,818,436 IB IB D15Mit35 15 61.7 103,347,764 IB D16Mit32 16 1.7 3,962,915 IB I D16Mit34 16 9.61 15,913,145 IB D16Mit101 16 17 23,737,062 IB D16Mit30 16 36.5 53,962,663 IB IB IB D16Mit139 16 43.1 65,669,762 IB D16Mit19 16 54 78,812,001 IB D16Mit153 16 56.8 87,583,609 I IB D17Mit134 17 16.9 30,882,736 I D17Mit16 17 17.4 33,737,692 IB IB D17Mit21 17 18.64 34,380,179 IB D17Mit67 17 25 49,391,029 IB D17Mit6 17 31 52,743,901 IB D17Mit7 17 32.3 53,677,823 IB D17Mit93 17 44.5 74,149,996 IB D17Mit39 17 45.3 74,681,434 IB D17Mit41 17 53 84,734,943 IB D18Mit21 18 6 15,691,773 IB D18Mit14 18 18 38,829,325 IB D18Mit35 18 24 45,135,967 IB D18Mit36 18 24 46,694,501 IB D18Mit91 18 29 55,539,802 IB D18Mit48 18 50 77,046,867 IB D18Mit7 18 50 77,086,365 IB D18Mit4 18 57 84,295,656 IB D19Mit16 19 15 20,420,342 IB IB D19Mit23 19 15 20,510,387 IB D19Mit13 19 33 32,713,513 IB D19Mit11 19 41 42,469,099 IB D19Mit38 19 47 47,260,633 IB D19Mit37 19 51 51,501,173 IB D19Mit33 19 53 56,270,122 IB D19Mit6 19 55 61,132,164 IB aPosition from Mouse Genome Informatics (http://www.informatics.jax.org).
Load more

Recommended publications
  • Small Cell Ovarian Carcinoma: Genomic Stability and Responsiveness to Therapeutics
    Gamwell et al. Orphanet Journal of Rare Diseases 2013, 8:33 http://www.ojrd.com/content/8/1/33 RESEARCH Open Access Small cell ovarian carcinoma: genomic stability and responsiveness to therapeutics Lisa F Gamwell1,2, Karen Gambaro3, Maria Merziotis2, Colleen Crane2, Suzanna L Arcand4, Valerie Bourada1,2, Christopher Davis2, Jeremy A Squire6, David G Huntsman7,8, Patricia N Tonin3,4,5 and Barbara C Vanderhyden1,2* Abstract Background: The biology of small cell ovarian carcinoma of the hypercalcemic type (SCCOHT), which is a rare and aggressive form of ovarian cancer, is poorly understood. Tumourigenicity, in vitro growth characteristics, genetic and genomic anomalies, and sensitivity to standard and novel chemotherapeutic treatments were investigated in the unique SCCOHT cell line, BIN-67, to provide further insight in the biology of this rare type of ovarian cancer. Method: The tumourigenic potential of BIN-67 cells was determined and the tumours formed in a xenograft model was compared to human SCCOHT. DNA sequencing, spectral karyotyping and high density SNP array analysis was performed. The sensitivity of the BIN-67 cells to standard chemotherapeutic agents and to vesicular stomatitis virus (VSV) and the JX-594 vaccinia virus was tested. Results: BIN-67 cells were capable of forming spheroids in hanging drop cultures. When xenografted into immunodeficient mice, BIN-67 cells developed into tumours that reflected the hypercalcemia and histology of human SCCOHT, notably intense expression of WT-1 and vimentin, and lack of expression of inhibin. Somatic mutations in TP53 and the most common activating mutations in KRAS and BRAF were not found in BIN-67 cells by DNA sequencing.
    [Show full text]
  • Molecular Biology and Biochemistry of The
    MOLECULAR BIOLOGY AND BIOCHEMISTRY OF THE REGULATION OF HRP/TYPE III SECRETION GENES IN THE CORN PATHOGEN PANTOEA STEWARTII SUBSP. STEWARTII DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Massimo Merighi, B. S., M. S. ***** The Ohio State University 2003 Dissertation Committee: Professor David L. Coplin, Adviser Approved by Professor Brian Ahmer ______________________ Professor Dietz W. Bauer Adviser Professor Terrence L. Graham Plant Pathology Copyright by Massimo Merighi 2003 ii ABSTRACT Pantoea stewartii subsp. stewartii is a bacterial pathogen of corn. Its pathogenicity depends on the expression of a Hrp/type III protein secretion/translocation system. The regulatory region of the hrp gene cluster consists of three adjacent operons: hrpXY encodes a two- component regulatory system, consisting of the response regulator HrpY and sensor PAS-kinase HrpX; hrpS encodes an NtrC-like enhancer-binding protein; and hrpL encodes an ECF sigma factor. In this study, we used genetic and biochemical approaches to delineate the following regulatory cascade: 1) HrpY activates hrpS; 2) HrpS activates hrpL; and 3) HrpL activates secretion and effector genes with ‘Hrp-box’ promoters. This pathway responds to environmental signals and global regulators. Mutant analysis showed that HrpX is required for full virulence. Deletion of its individual PAS-sensory domains revealed that they are not redundant and each may have a different role in modulating kinase activity. HrpX probably senses an intracellular signal, possibly related to nitrogen metabolism. pH, osmolarity and nicotinic acid controlled expression of hrpS independently of HrpX/HrpY.
    [Show full text]
  • A Genome-Wide Association Study Lystra P
    Hayden et al. Respiratory Research (2018) 19:209 https://doi.org/10.1186/s12931-018-0890-0 RESEARCH Open Access Childhood asthma is associated with COPD and known asthma variants in COPDGene: a genome-wide association study Lystra P. Hayden1,2* , Michael H. Cho2,3, Benjamin A. Raby1,2,3, Terri H. Beaty4, Edwin K. Silverman2,3, Craig P. Hersh2,3 and on behalf of the COPDGene Investigators Abstract Background: Childhood asthma is strongly influenced by genetics and is a risk factor for reduced lung function and chronic obstructive pulmonary disease (COPD) in adults. This study investigates self-reported childhood asthma in adult smokers from the COPDGene Study. We hypothesize that childhood asthma is associated with decreased lung function, increased risk for COPD, and that a genome-wide association study (GWAS) will show association with established asthma variants. Methods: We evaluated current and former smokers ages 45–80 of non-Hispanic white (NHW) or African American (AA) race. Childhood asthma was defined by self-report of asthma, diagnosed by a medical professional, with onset at < 16 years or during childhood. Subjects with a history of childhood asthma were compared to those who never had asthma based on lung function, development of COPD, and genetic variation. GWAS was performed in NHW and AA populations, and combined in meta-analysis. Two sets of established asthma SNPs from published literature were examined for association with childhood asthma. Results: Among 10,199 adult smokers, 730 (7%) reported childhood asthma and 7493 (73%) reported no history of asthma. Childhood asthmatics had reduced lung function and increased risk for COPD (OR 3.42, 95% CI 2.81–4.18).
    [Show full text]
  • Atg4b Antibody A
    Revision 1 C 0 2 - t Atg4B Antibody a e r o t S Orders: 877-616-CELL (2355) [email protected] Support: 877-678-TECH (8324) 9 9 Web: [email protected] 2 www.cellsignal.com 5 # 3 Trask Lane Danvers Massachusetts 01923 USA For Research Use Only. Not For Use In Diagnostic Procedures. Applications: Reactivity: Sensitivity: MW (kDa): Source: UniProt ID: Entrez-Gene Id: WB H M R Endogenous 48 Rabbit Q9Y4P1 23192 Product Usage Information 2. Ohsumi, Y. (2001) Nat Rev Mol Cell Biol 2, 211-6. 3. Kabeya, Y. et al. (2000) EMBO J 19, 5720-8. Application Dilution 4. Kabeya, Y. et al. (2004) J Cell Sci 117, 2805-12. 5. Mariño, G. et al. (2003) J Biol Chem 278, 3671-8. Western Blotting 1:1000 6. Sou, Y.S. et al. (2008) Mol Biol Cell 19, 4762-75. 7. Hemelaar, J. et al. (2003) J Biol Chem 278, 51841-50. Storage 8. Kabeya, Y. et al. (2004) J Cell Sci 117, 2805-12. 9. Tanida, I. et al. (2004) J Biol Chem 279, 36268-76. Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% 10. Fujita, N. et al. (2008) Mol Biol Cell 19, 4651-9. glycerol. Store at –20°C. Do not aliquot the antibody. 11. Fujita, N. et al. (2009) Autophagy 5, 88-9. Specificity / Sensitivity Atg4B Antibody detects endogenous levels of total Atg4B protein. This antibody detects a band at ~27 kDa of unknown origin. Species Reactivity: Human, Mouse, Rat Source / Purification Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ser372 of human Atg4B protein.
    [Show full text]
  • Phosphatidylethanolamine Positively Regulates Autophagy and Longevity
    Cell Death and Differentiation (2015) 22, 499–508 OPEN & 2015 Macmillan Publishers Limited All rights reserved 1350-9047/15 www.nature.com/cdd Phosphatidylethanolamine positively regulates autophagy and longevity P Rockenfeller1, M Koska1, F Pietrocola2, N Minois3, O Knittelfelder1, V Sica2, J Franz1, D Carmona-Gutierrez1, G Kroemer*,2,4,5,6,7 and F Madeo*,1,8 Autophagy is a cellular recycling program that retards ageing by efficiently eliminating damaged and potentially harmful organelles and intracellular protein aggregates. Here, we show that the abundance of phosphatidylethanolamine (PE) positively regulates autophagy. Reduction of intracellular PE levels by knocking out either of the two yeast phosphatidylserine decarboxylases (PSD) accelerated chronological ageing-associated production of reactive oxygen species and death. Conversely, the artificial increase of intracellular PE levels, by provision of its precursor ethanolamine or by overexpression of the PE-generating enzyme Psd1, significantly increased autophagic flux, both in yeast and in mammalian cell culture. Importantly administration of ethanolamine was sufficient to extend the lifespan of yeast (Saccharomyces cerevisiae), mammalian cells (U2OS, H4) and flies (Drosophila melanogaster). We thus postulate that the availability of PE may constitute a bottleneck for functional autophagy and that organismal life or healthspan could be positively influenced by the consumption of ethanolamine-rich food. Cell Death and Differentiation (2015) 22, 499–508; doi:10.1038/cdd.2014.219; published online 9 January 2015 Phosphatidylethanolamine (PE) is a phospholipid found in all linked to ageing. Autophagy mainly differs from the proteaso- living organisms. Together with phosphatidylcholine (PC), mal pathway, the other major cellular degradation mechanism, phosphatidylserine (PS) and phosphatidylinositol (PI), PE in two aspects.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Functional Screening of Alzheimer Risk Loci Identifies PTK2B
    OPEN Molecular Psychiatry (2017) 22, 874–883 www.nature.com/mp ORIGINAL ARTICLE Functional screening of Alzheimer risk loci identifies PTK2B as an in vivo modulator and early marker of Tau pathology P Dourlen1,2,3, FJ Fernandez-Gomez4,5,6, C Dupont1,2,3, B Grenier-Boley1,2,3, C Bellenguez1,2,3, H Obriot4,5,6, R Caillierez4,5,6, Y Sottejeau1,2,3, J Chapuis1,2,3, A Bretteville1,2,3, F Abdelfettah1,2,3, C Delay1,2,3, N Malmanche1,2,3, H Soininen7, M Hiltunen7,8, M-C Galas4,5,6, P Amouyel1,2,3,9, N Sergeant4,5,6, L Buée4,5,6, J-C Lambert1,2,3,11 and B Dermaut1,2,3,10,11 A recent genome-wide association meta-analysis for Alzheimer’s disease (AD) identified 19 risk loci (in addition to APOE) in which the functional genes are unknown. Using Drosophila, we screened 296 constructs targeting orthologs of 54 candidate risk genes within these loci for their ability to modify Tau neurotoxicity by quantifying the size of 46000 eyes. Besides Drosophila Amph (ortholog of BIN1), which we previously implicated in Tau pathology, we identified p130CAS (CASS4), Eph (EPHA1), Fak (PTK2B) and Rab3-GEF (MADD) as Tau toxicity modulators. Of these, the focal adhesion kinase Fak behaved as a strong Tau toxicity suppressor in both the eye and an independent focal adhesion-related wing blister assay. Accordingly, the human Tau and PTK2B proteins biochemically interacted in vitro and PTK2B co-localized with hyperphosphorylated and oligomeric Tau in progressive pathological stages in the brains of AD patients and transgenic Tau mice.
    [Show full text]
  • 4-6 Weeks Old Female C57BL/6 Mice Obtained from Jackson Labs Were Used for Cell Isolation
    Methods Mice: 4-6 weeks old female C57BL/6 mice obtained from Jackson labs were used for cell isolation. Female Foxp3-IRES-GFP reporter mice (1), backcrossed to B6/C57 background for 10 generations, were used for the isolation of naïve CD4 and naïve CD8 cells for the RNAseq experiments. The mice were housed in pathogen-free animal facility in the La Jolla Institute for Allergy and Immunology and were used according to protocols approved by the Institutional Animal Care and use Committee. Preparation of cells: Subsets of thymocytes were isolated by cell sorting as previously described (2), after cell surface staining using CD4 (GK1.5), CD8 (53-6.7), CD3ε (145- 2C11), CD24 (M1/69) (all from Biolegend). DP cells: CD4+CD8 int/hi; CD4 SP cells: CD4CD3 hi, CD24 int/lo; CD8 SP cells: CD8 int/hi CD4 CD3 hi, CD24 int/lo (Fig S2). Peripheral subsets were isolated after pooling spleen and lymph nodes. T cells were enriched by negative isolation using Dynabeads (Dynabeads untouched mouse T cells, 11413D, Invitrogen). After surface staining for CD4 (GK1.5), CD8 (53-6.7), CD62L (MEL-14), CD25 (PC61) and CD44 (IM7), naïve CD4+CD62L hiCD25-CD44lo and naïve CD8+CD62L hiCD25-CD44lo were obtained by sorting (BD FACS Aria). Additionally, for the RNAseq experiments, CD4 and CD8 naïve cells were isolated by sorting T cells from the Foxp3- IRES-GFP mice: CD4+CD62LhiCD25–CD44lo GFP(FOXP3)– and CD8+CD62LhiCD25– CD44lo GFP(FOXP3)– (antibodies were from Biolegend). In some cases, naïve CD4 cells were cultured in vitro under Th1 or Th2 polarizing conditions (3, 4).
    [Show full text]
  • Cysteine Proteases in Protozoan Parasites
    UC San Diego UC San Diego Previously Published Works Title Cysteine proteases in protozoan parasites. Permalink https://escholarship.org/uc/item/6sb6c27b Journal PLoS neglected tropical diseases, 12(8) ISSN 1935-2727 Authors Siqueira-Neto, Jair L Debnath, Anjan McCall, Laura-Isobel et al. Publication Date 2018-08-23 DOI 10.1371/journal.pntd.0006512 Peer reviewed eScholarship.org Powered by the California Digital Library University of California REVIEW Cysteine proteases in protozoan parasites Jair L. Siqueira-Neto1*, Anjan Debnath1, Laura-Isobel McCall1¤, Jean A. Bernatchez1, Momar Ndao2,3, Sharon L. Reed4, Philip J. Rosenthal5 1 Center for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California, United States of America, 2 National Reference Centre for Parasitology, The Research Institute of the McGill University Health Center, Montreal, Canada, 3 Program in Infectious Diseases and Immunity in Global Health, The Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada, 4 Departments of Pathology and Medicine, University of California San Diego School of Medicine, La Jolla, California, United States of America, 5 Department of Medicine, University of California, San Francisco, San Francisco, California, a1111111111 United States of America a1111111111 a1111111111 ¤ Current address: Department of Chemistry and Biochemistry, University of Oklahoma, Norman, Oklahoma, a1111111111 United States of America a1111111111 * [email protected] Abstract OPEN ACCESS Cysteine proteases (CPs) play key roles in the pathogenesis of protozoan parasites, includ- Citation: Siqueira-Neto JL, Debnath A, McCall L-I, ing cell/tissue penetration, hydrolysis of host or parasite proteins, autophagy, and evasion Bernatchez JA, Ndao M, Reed SL, et al.
    [Show full text]
  • Anti-NFYC Antibody (ARG66549)
    Product datasheet [email protected] ARG66549 Package: 100 μl anti-NFYC antibody Store at: -20°C Summary Product Description Rabbit Polyclonal antibody recognizes NFYC Tested Reactivity Hu, Ms Tested Application IHC-P, WB Host Rabbit Clonality Polyclonal Isotype IgG Target Name NFYC Antigen Species Human Immunogen KLH-conjugated synthetic peptide encompassing a sequence within the N-term region of Human NFYC. Conjugation Un-conjugated Alternate Names HAP5; NF-YC; Nuclear transcription factor Y subunit gamma; Nuclear transcription factor Y subunit C; CBF-C; HSM; CBFC; Transactivator HSM-1/2; CAAT box DNA-binding protein subunit C; H1TF2A Application Instructions Application table Application Dilution IHC-P 1:100 - 1:200 WB 1:500 - 1:1000 Application Note IHC-P: Antigen Retrieval: Heat mediation was performed in Sodium citrate buffer (pH 6.0). * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist. Calculated Mw 50 kDa Observed Size 50 kDa Properties Form Liquid Purification Affinity purification with immunogen. Buffer 0.42% Potassium phosphate (pH 7.3), 0.87% NaCl, 0.01% Sodium azide and 30% Glycerol. Preservative 0.01% Sodium azide Stabilizer 30% Glycerol Storage instruction For continuous use, store undiluted antibody at 2-8°C for up to a week. For long-term storage, aliquot and store at -20°C. Storage in frost free freezers is not recommended. Avoid repeated freeze/thaw cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use. www.arigobio.com 1/2 Note For laboratory research only, not for drug, diagnostic or other use.
    [Show full text]
  • Cellular and Molecular Signatures in the Disease Tissue of Early
    Cellular and Molecular Signatures in the Disease Tissue of Early Rheumatoid Arthritis Stratify Clinical Response to csDMARD-Therapy and Predict Radiographic Progression Frances Humby1,* Myles Lewis1,* Nandhini Ramamoorthi2, Jason Hackney3, Michael Barnes1, Michele Bombardieri1, Francesca Setiadi2, Stephen Kelly1, Fabiola Bene1, Maria di Cicco1, Sudeh Riahi1, Vidalba Rocher-Ros1, Nora Ng1, Ilias Lazorou1, Rebecca E. Hands1, Desiree van der Heijde4, Robert Landewé5, Annette van der Helm-van Mil4, Alberto Cauli6, Iain B. McInnes7, Christopher D. Buckley8, Ernest Choy9, Peter Taylor10, Michael J. Townsend2 & Costantino Pitzalis1 1Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK. Departments of 2Biomarker Discovery OMNI, 3Bioinformatics and Computational Biology, Genentech Research and Early Development, South San Francisco, California 94080 USA 4Department of Rheumatology, Leiden University Medical Center, The Netherlands 5Department of Clinical Immunology & Rheumatology, Amsterdam Rheumatology & Immunology Center, Amsterdam, The Netherlands 6Rheumatology Unit, Department of Medical Sciences, Policlinico of the University of Cagliari, Cagliari, Italy 7Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow G12 8TA, UK 8Rheumatology Research Group, Institute of Inflammation and Ageing (IIA), University of Birmingham, Birmingham B15 2WB, UK 9Institute of
    [Show full text]
  • Genome-Wide DNA Methylation Analysis of KRAS Mutant Cell Lines Ben Yi Tew1,5, Joel K
    www.nature.com/scientificreports OPEN Genome-wide DNA methylation analysis of KRAS mutant cell lines Ben Yi Tew1,5, Joel K. Durand2,5, Kirsten L. Bryant2, Tikvah K. Hayes2, Sen Peng3, Nhan L. Tran4, Gerald C. Gooden1, David N. Buckley1, Channing J. Der2, Albert S. Baldwin2 ✉ & Bodour Salhia1 ✉ Oncogenic RAS mutations are associated with DNA methylation changes that alter gene expression to drive cancer. Recent studies suggest that DNA methylation changes may be stochastic in nature, while other groups propose distinct signaling pathways responsible for aberrant methylation. Better understanding of DNA methylation events associated with oncogenic KRAS expression could enhance therapeutic approaches. Here we analyzed the basal CpG methylation of 11 KRAS-mutant and dependent pancreatic cancer cell lines and observed strikingly similar methylation patterns. KRAS knockdown resulted in unique methylation changes with limited overlap between each cell line. In KRAS-mutant Pa16C pancreatic cancer cells, while KRAS knockdown resulted in over 8,000 diferentially methylated (DM) CpGs, treatment with the ERK1/2-selective inhibitor SCH772984 showed less than 40 DM CpGs, suggesting that ERK is not a broadly active driver of KRAS-associated DNA methylation. KRAS G12V overexpression in an isogenic lung model reveals >50,600 DM CpGs compared to non-transformed controls. In lung and pancreatic cells, gene ontology analyses of DM promoters show an enrichment for genes involved in diferentiation and development. Taken all together, KRAS-mediated DNA methylation are stochastic and independent of canonical downstream efector signaling. These epigenetically altered genes associated with KRAS expression could represent potential therapeutic targets in KRAS-driven cancer. Activating KRAS mutations can be found in nearly 25 percent of all cancers1.
    [Show full text]